| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 31 | 2020 | 1209 | 6.150 |
Why?
|
| Atherosclerosis | 32 | 2020 | 837 | 6.140 |
Why?
|
| Coronary Artery Disease | 33 | 2020 | 441 | 5.760 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 17 | 2019 | 168 | 4.630 |
Why?
|
| Cardiology | 7 | 2019 | 110 | 2.760 |
Why?
|
| Primary Prevention | 13 | 2019 | 57 | 2.660 |
Why?
|
| Risk Assessment | 32 | 2020 | 1508 | 2.230 |
Why?
|
| Ethnic Groups | 20 | 2019 | 483 | 2.220 |
Why?
|
| Coronary Vessels | 13 | 2019 | 180 | 2.190 |
Why?
|
| Calcium | 9 | 2019 | 343 | 2.040 |
Why?
|
| Risk Factors | 50 | 2020 | 4137 | 2.030 |
Why?
|
| Cholesterol | 5 | 2018 | 273 | 1.970 |
Why?
|
| Vasodilation | 11 | 2019 | 96 | 1.950 |
Why?
|
| Brachial Artery | 10 | 2019 | 76 | 1.940 |
Why?
|
| Aged | 66 | 2020 | 11022 | 1.840 |
Why?
|
| American Heart Association | 8 | 2019 | 92 | 1.780 |
Why?
|
| Proportional Hazards Models | 25 | 2020 | 804 | 1.760 |
Why?
|
| Practice Guidelines as Topic | 9 | 2019 | 431 | 1.730 |
Why?
|
| Middle Aged | 66 | 2020 | 12726 | 1.680 |
Why?
|
| Coronary Angiography | 13 | 2020 | 168 | 1.620 |
Why?
|
| Aged, 80 and over | 39 | 2019 | 4157 | 1.610 |
Why?
|
| Humans | 90 | 2020 | 34562 | 1.510 |
Why?
|
| United States | 37 | 2019 | 4278 | 1.490 |
Why?
|
| Male | 72 | 2020 | 20740 | 1.470 |
Why?
|
| Female | 71 | 2020 | 21532 | 1.450 |
Why?
|
| Diabetes Complications | 4 | 2018 | 189 | 1.450 |
Why?
|
| Heart Failure | 10 | 2020 | 780 | 1.430 |
Why?
|
| Incidence | 24 | 2020 | 1290 | 1.420 |
Why?
|
| Anticholesteremic Agents | 4 | 2018 | 47 | 1.390 |
Why?
|
| Cohort Studies | 22 | 2020 | 1910 | 1.350 |
Why?
|
| Blood Pressure | 8 | 2020 | 901 | 1.250 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2020 | 1523 | 1.170 |
Why?
|
| Hyperlipidemias | 2 | 2018 | 61 | 1.100 |
Why?
|
| Predictive Value of Tests | 17 | 2018 | 939 | 1.100 |
Why?
|
| Hypercholesterolemia | 2 | 2018 | 74 | 1.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 230 | 1.040 |
Why?
|
| Endothelium, Vascular | 7 | 2019 | 163 | 1.020 |
Why?
|
| Coronary Disease | 5 | 2018 | 239 | 1.010 |
Why?
|
| Prospective Studies | 21 | 2020 | 2463 | 1.010 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 455 | 0.940 |
Why?
|
| C-Reactive Protein | 5 | 2018 | 248 | 0.860 |
Why?
|
| Atrial Fibrillation | 7 | 2020 | 411 | 0.840 |
Why?
|
| Antihypertensive Agents | 5 | 2020 | 379 | 0.840 |
Why?
|
| Asian Americans | 7 | 2019 | 96 | 0.840 |
Why?
|
| Stroke | 5 | 2018 | 700 | 0.830 |
Why?
|
| Prognosis | 18 | 2019 | 1606 | 0.800 |
Why?
|
| Hypertension | 7 | 2020 | 1024 | 0.780 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 2367 | 0.780 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 104 | 0.770 |
Why?
|
| European Continental Ancestry Group | 8 | 2018 | 1176 | 0.720 |
Why?
|
| Ankle Brachial Index | 4 | 2016 | 40 | 0.700 |
Why?
|
| Body Height | 3 | 2017 | 36 | 0.690 |
Why?
|
| Cause of Death | 10 | 2019 | 245 | 0.680 |
Why?
|
| Body Mass Index | 5 | 2018 | 954 | 0.650 |
Why?
|
| Hunger | 1 | 2020 | 5 | 0.640 |
Why?
|
| Long QT Syndrome | 1 | 2020 | 44 | 0.630 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2020 | 103 | 0.630 |
Why?
|
| Food Supply | 1 | 2020 | 68 | 0.600 |
Why?
|
| Smoking | 4 | 2018 | 544 | 0.600 |
Why?
|
| African Americans | 8 | 2020 | 1435 | 0.600 |
Why?
|
| Poverty | 1 | 2020 | 118 | 0.600 |
Why?
|
| Hemorheology | 3 | 2007 | 8 | 0.590 |
Why?
|
| Stroke Volume | 3 | 2020 | 440 | 0.580 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2016 | 109 | 0.580 |
Why?
|
| Thorax | 1 | 2018 | 32 | 0.580 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 302 | 0.570 |
Why?
|
| Hispanic Americans | 7 | 2018 | 948 | 0.550 |
Why?
|
| Stress, Psychological | 1 | 2020 | 233 | 0.550 |
Why?
|
| Carotid Artery Diseases | 4 | 2018 | 129 | 0.550 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 44 | 0.540 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2008 | 115 | 0.530 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 287 | 0.510 |
Why?
|
| Time Factors | 12 | 2019 | 2353 | 0.510 |
Why?
|
| Edema, Cardiac | 1 | 2016 | 14 | 0.500 |
Why?
|
| Body Weight | 1 | 2018 | 343 | 0.500 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2020 | 988 | 0.500 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2008 | 222 | 0.490 |
Why?
|
| Aorta, Thoracic | 4 | 2020 | 87 | 0.490 |
Why?
|
| Multivariate Analysis | 12 | 2019 | 703 | 0.490 |
Why?
|
| Heptanoic Acids | 2 | 2014 | 35 | 0.480 |
Why?
|
| Pyrroles | 2 | 2014 | 62 | 0.470 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 326 | 0.470 |
Why?
|
| Family Health | 1 | 2016 | 79 | 0.470 |
Why?
|
| Snoring | 2 | 2015 | 10 | 0.460 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 35 | 0.460 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2015 | 28 | 0.460 |
Why?
|
| Health Status | 2 | 2019 | 411 | 0.450 |
Why?
|
| Ischemic Attack, Transient | 2 | 2017 | 57 | 0.450 |
Why?
|
| Aortography | 2 | 2016 | 16 | 0.430 |
Why?
|
| Postmenopause | 3 | 2019 | 461 | 0.430 |
Why?
|
| Blood Glucose | 2 | 2020 | 529 | 0.420 |
Why?
|
| Sphingomyelins | 2 | 2014 | 8 | 0.420 |
Why?
|
| Diabetes Mellitus | 3 | 2018 | 439 | 0.400 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 124 | 0.390 |
Why?
|
| Niacin | 1 | 2012 | 7 | 0.380 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 15 | 0.380 |
Why?
|
| African Continental Ancestry Group | 2 | 2011 | 367 | 0.380 |
Why?
|
| Advisory Committees | 4 | 2019 | 37 | 0.370 |
Why?
|
| Age Factors | 8 | 2018 | 1262 | 0.370 |
Why?
|
| Survival Analysis | 4 | 2018 | 510 | 0.370 |
Why?
|
| Calcinosis | 3 | 2017 | 150 | 0.360 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2012 | 184 | 0.340 |
Why?
|
| Aortic Diseases | 3 | 2017 | 67 | 0.340 |
Why?
|
| Hyperemia | 2 | 2009 | 11 | 0.340 |
Why?
|
| Chi-Square Distribution | 5 | 2015 | 305 | 0.340 |
Why?
|
| Carotid Arteries | 2 | 2010 | 116 | 0.330 |
Why?
|
| Prevalence | 8 | 2018 | 1034 | 0.330 |
Why?
|
| Vascular Fistula | 1 | 2010 | 4 | 0.320 |
Why?
|
| Fistula | 1 | 2010 | 11 | 0.320 |
Why?
|
| Adult | 12 | 2020 | 10030 | 0.320 |
Why?
|
| Risk Reduction Behavior | 3 | 2019 | 129 | 0.310 |
Why?
|
| Vitamin D | 1 | 2011 | 187 | 0.310 |
Why?
|
| Dietary Supplements | 1 | 2011 | 198 | 0.310 |
Why?
|
| Models, Cardiovascular | 1 | 2009 | 33 | 0.300 |
Why?
|
| Treatment Outcome | 5 | 2018 | 3623 | 0.300 |
Why?
|
| ROC Curve | 4 | 2016 | 176 | 0.290 |
Why?
|
| Heart Diseases | 1 | 2010 | 124 | 0.290 |
Why?
|
| Medication Therapy Management | 2 | 2018 | 11 | 0.290 |
Why?
|
| Sex Factors | 6 | 2017 | 708 | 0.290 |
Why?
|
| Eligibility Determination | 2 | 2018 | 18 | 0.290 |
Why?
|
| Consensus | 2 | 2018 | 92 | 0.280 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 159 | 0.270 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2019 | 89 | 0.270 |
Why?
|
| Dyslipidemias | 2 | 2018 | 61 | 0.270 |
Why?
|
| Morbidity | 2 | 2019 | 103 | 0.270 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 35 | 0.260 |
Why?
|
| Contraceptive Agents, Female | 1 | 2007 | 15 | 0.260 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 922 | 0.260 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2007 | 16 | 0.250 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 21 | 0.250 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 803 | 0.250 |
Why?
|
| Diabetic Angiopathies | 2 | 2019 | 153 | 0.240 |
Why?
|
| Ultrasonography | 5 | 2014 | 417 | 0.240 |
Why?
|
| Risk | 3 | 2018 | 325 | 0.240 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1607 | 0.240 |
Why?
|
| Area Under Curve | 3 | 2018 | 98 | 0.240 |
Why?
|
| Estrogens | 1 | 2007 | 210 | 0.230 |
Why?
|
| Hospitalization | 2 | 2020 | 500 | 0.230 |
Why?
|
| Heart Atria | 2 | 2020 | 84 | 0.230 |
Why?
|
| Heart Rate | 2 | 2020 | 372 | 0.230 |
Why?
|
| Peptide Fragments | 2 | 2019 | 430 | 0.220 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 823 | 0.220 |
Why?
|
| Regional Blood Flow | 3 | 2009 | 95 | 0.210 |
Why?
|
| Discriminant Analysis | 2 | 2014 | 22 | 0.210 |
Why?
|
| Disease Progression | 5 | 2017 | 634 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2020 | 3825 | 0.200 |
Why?
|
| Reference Values | 2 | 2016 | 265 | 0.190 |
Why?
|
| Myocardial Infarction | 2 | 2019 | 515 | 0.190 |
Why?
|
| Inhibitor of Differentiation Proteins | 2 | 2014 | 2 | 0.190 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 157 | 0.170 |
Why?
|
| Logistic Models | 3 | 2020 | 808 | 0.170 |
Why?
|
| Survival Rate | 3 | 2019 | 928 | 0.160 |
Why?
|
| Lipids | 2 | 2019 | 267 | 0.160 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 354 | 0.160 |
Why?
|
| Ghana | 1 | 2020 | 24 | 0.160 |
Why?
|
| Comorbidity | 3 | 2020 | 596 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2018 | 258 | 0.160 |
Why?
|
| Independent Living | 1 | 2020 | 95 | 0.150 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 42 | 0.150 |
Why?
|
| Tunica Media | 2 | 2010 | 41 | 0.150 |
Why?
|
| Thrombosis | 1 | 2019 | 88 | 0.140 |
Why?
|
| Periodontal Diseases | 1 | 2018 | 18 | 0.140 |
Why?
|
| Tunica Intima | 2 | 2010 | 81 | 0.140 |
Why?
|
| Stress, Mechanical | 2 | 2009 | 102 | 0.140 |
Why?
|
| Medicaid | 1 | 2018 | 105 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 318 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 1079 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 29 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2016 | 508 | 0.140 |
Why?
|
| Incidental Findings | 1 | 2018 | 26 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 261 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 200 | 0.130 |
Why?
|
| Diabetic Nephropathies | 1 | 2019 | 228 | 0.130 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 185 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 136 | 0.130 |
Why?
|
| Medicare | 1 | 2018 | 224 | 0.130 |
Why?
|
| Aortic Valve | 2 | 2017 | 60 | 0.130 |
Why?
|
| Continental Population Groups | 1 | 2018 | 245 | 0.130 |
Why?
|
| Research | 1 | 2017 | 88 | 0.130 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 156 | 0.120 |
Why?
|
| Hypotension, Orthostatic | 1 | 2016 | 15 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 291 | 0.120 |
Why?
|
| Posture | 1 | 2016 | 63 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 51 | 0.120 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 194 | 0.120 |
Why?
|
| Vascular Resistance | 1 | 2015 | 33 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2016 | 75 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 614 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 315 | 0.110 |
Why?
|
| Arteries | 1 | 2015 | 83 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 28 | 0.110 |
Why?
|
| Diet | 1 | 2017 | 418 | 0.110 |
Why?
|
| Germany | 1 | 2014 | 7 | 0.110 |
Why?
|
| Neoplasms | 3 | 2018 | 793 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2014 | 155 | 0.110 |
Why?
|
| Young Adult | 2 | 2019 | 2831 | 0.110 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 77 | 0.110 |
Why?
|
| Anthracyclines | 1 | 2014 | 62 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2014 | 194 | 0.100 |
Why?
|
| Emphysema | 1 | 2014 | 12 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 83 | 0.100 |
Why?
|
| Age Distribution | 1 | 2014 | 211 | 0.100 |
Why?
|
| Endpoint Determination | 1 | 2013 | 22 | 0.100 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 87 | 0.100 |
Why?
|
| Body Composition | 1 | 2015 | 415 | 0.100 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 31 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 849 | 0.100 |
Why?
|
| Mitral Valve | 1 | 2013 | 41 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 75 | 0.090 |
Why?
|
| Doxorubicin | 1 | 2013 | 92 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2015 | 926 | 0.090 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2010 | 6 | 0.080 |
Why?
|
| Echocardiography, Stress | 1 | 2010 | 28 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 89 | 0.080 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 61 | 0.080 |
Why?
|
| Ultrasonography, Doppler | 1 | 2009 | 24 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 628 | 0.080 |
Why?
|
| Kinetics | 1 | 2009 | 259 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.070 |
Why?
|
| E-Selectin | 1 | 2008 | 21 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 43 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 69 | 0.070 |
Why?
|
| Mortality | 2 | 2018 | 127 | 0.070 |
Why?
|
| Tourniquets | 1 | 2007 | 12 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2007 | 9 | 0.060 |
Why?
|
| Animals | 3 | 2013 | 8579 | 0.060 |
Why?
|
| Obesity | 1 | 2014 | 1246 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 145 | 0.060 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2017 | 18 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2007 | 597 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 260 | 0.060 |
Why?
|
| Electrocardiography | 2 | 2020 | 657 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2014 | 222 | 0.040 |
Why?
|
| Mississippi | 1 | 2020 | 38 | 0.040 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 26 | 0.040 |
Why?
|
| Dehydroepiandrosterone | 1 | 2019 | 11 | 0.040 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2019 | 15 | 0.040 |
Why?
|
| Androgens | 1 | 2019 | 32 | 0.040 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2019 | 14 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2019 | 122 | 0.040 |
Why?
|
| Testosterone | 1 | 2019 | 51 | 0.040 |
Why?
|
| Estradiol | 1 | 2019 | 156 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2018 | 109 | 0.040 |
Why?
|
| Brazil | 1 | 2018 | 16 | 0.040 |
Why?
|
| Social Class | 1 | 2018 | 94 | 0.030 |
Why?
|
| Educational Status | 1 | 2018 | 185 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 755 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2017 | 109 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 439 | 0.030 |
Why?
|
| Ischemia | 1 | 2017 | 119 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 142 | 0.030 |
Why?
|
| Systole | 1 | 2016 | 103 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 153 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2016 | 108 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 43 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 30 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 248 | 0.030 |
Why?
|
| Life Style | 1 | 2017 | 418 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 2015 | 12 | 0.030 |
Why?
|
| Baltimore | 1 | 2015 | 50 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 557 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 188 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 465 | 0.030 |
Why?
|
| Echocardiography | 1 | 2015 | 202 | 0.030 |
Why?
|
| Brugada Syndrome | 1 | 2014 | 18 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 73 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 168 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 380 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 261 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 2014 | 80 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2013 | 51 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2015 | 366 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 744 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 306 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 923 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 36 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 45 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 66 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2010 | 91 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2010 | 62 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 45 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2015 | 850 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 216 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 255 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 341 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 486 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 1946 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 657 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 526 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 842 | 0.020 |
Why?
|
| Adolescent | 1 | 2015 | 3805 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 1129 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 2720 | 0.010 |
Why?
|